Merck Family Names New Leadership for E. Merck Executive Board

07-Aug-2002

Darmstadt August 6, 2002 - Merck KGaA today announced leadership changes on the Board of E. Merck. This company, which is legally structured as a general partnership, represents the Merck Family interests in the pharmaceuticals and chemicals group, Merck KGaA.

Prof. Dr. Hans Joachim Langmann (77), Chairman of the Executive Board of E. Merck for 32 years, retired from this position on June 22, 2002, but will remain a member of the Executive Board. He also continues to act as Chairman of the Merck Family Council, a part of E. Merck that participates in fundamental business decisions. Prof. Langmann withdrew from the operating business in June 2000, when he retired after 35 years as Chairman of the Executive Board of Merck KGaA.

Jon Baumhauer (58) has been appointed Chairman of the Executive Board of E. Merck and Dr. Frank Stangenberg-Haverkamp (53) Vice Chairman. The CEO and Chairman of the Executive Board of Merck KGaA, Prof. Dr. Bernhard Scheuble (48), as well as the Chief Financial Officer of Merck KGaA, Dr. Michael Becker (54), will remain members of the Executive Board of E. Merck.

Prof. Dr. Thomas Schreckenbach, Dr. Jan Sombroek and Dr. Michael Römer have resigned from the Board of E. Merck.

"These succession measures within the Merck Family highlight our majority shareholder's clear commitment to the continuity and long-term perspective of the company," said Prof. Scheuble. "Likewise, in spite of the on-going consolidation in the pharmaceuticals and chemicals industries, Merck is determined to remain an independent company and to grow and secure its future through the strength of its own innovative products and services."

The Executive Board of E. Merck does not have any direct influence on the operating business of the Merck Group. It serves, rather, as the communications link between Merck KGaA, the hub of the Group's business operations, and E. Merck, which represents the interests of the Merck Family. The Executive Board of E. Merck also advises the leadership of Merck KGaA regarding decisions or projects that are subject to approval by the oversight bodies of E. Merck.

Jon Baumhauer studied history, philosophy and clinical psychology in New York and Munich, and has been a psychotherapist for more than 20 years. He was appointed to the Board of Partners of E. Merck in 1979 and has been its Chairman since 1994. The Board of Partners functions as an oversight body for Merck KGaA and appoints its Executive Board members. Mr. Baumhauer is married and has four children.

Dr. Frank Stangenberg-Haverkamp studied economics and economic history in Freiburg, and worked in international investment banking for more than 20 years. He was appointed to the Board of Partners of E. Merck in 1984 and has been its Vice Chairman since 1994. Dr. Stangenberg-Haverkamp is married and has seven children.

https://www.chemeurope.com/en/news/12846/merck-family-names-new-leadership-for-e-merck-executive-board.html